Canaccord analyst Kenric Tyghe initiated coverage of Cronos Group (CRON) with a Buy rating and C$4.25 price target While Canada and Israel are the company’s two largest markets today, the firm believes that its recent acquisition of CanAdelaar and the expansion of Cronos Growing Company are “the leading edge of transformational change at the company,” the analyst tells investors in a note starting coverage of the the Canadian cannabis group.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRON:
- Trump Trade: U.S. delays tariffs on Chinese semiconductors
- Trump orders rescheduling of cannabis by end of January, Marijuana Herald says
- Trump Trade: Trump increasing medical marijuana, cannabidiol research
- Here’s Why Penny Stock SMX Is Climbing Today
- Alliance Global says mandate for cannabis banking could come at another time